title: In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues.
abstract: GnRH analogues are effective targeting moieties and able to deliver anticancer agents selectively into malignant tumor cells which highly express GnRH receptors. However, the quantitative analysis of GnRH analogues' cellular uptake and the investigated cell types in GnRH-based drug delivery systems are currently limited. Previously introduced, selectively labeled fluorescent GnRH I, -II and -III derivatives provide great detectability, and they have suitable chemical properties for reproducible and robust experiments. We also found that the appropriate up-to-date methods with these labeled GnRH analogues could offer novel information about the GnRH-based drug delivery systems. This manuscript introduces some simple and fast experiments regarding the cellular uptake of [D-Lys6(FITC)]-GnRH-I, [D-Lys6(FITC)]-GnRH-II and [Lys8(FITC)]-GnRH-III on the EBC-1 (lung), the BxPC-3 (pancreas) and on the Detroit-562- (pharynx) malignant tumor cells. In parallel with these GnRH-FITC conjugates, the cell surface level of GnRH-I receptors was also examined on these cell lines before and after the GnRH treatment by confocal laser scanning microscopy. The cellular uptake of GnRH-FITC conjugates was quantified by fluorescence-activated cell sorting. In these experiments minor differences among GnRH analogues and major differences among cell types was observed. The significant differences among cell lines are correlated with their distinct level of cell surface GnRH-I receptors. The introduced experiments contain practical methods to visualize, quantify and compare the uptake efficiency of GnRH-FITC conjugates in a time- and concentration-dependent manner on various adherent cell cultures. These results could predict the drug targeting efficiency of GnRH conjugates on the given cell culture, and offer a good basis for further experiments in the examination of GnRH-based drug delivery systems.
authors.affiliation: MTA-SE Pathobiochemistry Research Group, Semmelweis University; Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University; muranyi.jozsef@med.semmelweis-univ.hu.
authors.forename: József
authors.initials: J
authors.lastname: Murányi
authors.affiliation: MTA-SE Pathobiochemistry Research Group, Semmelweis University.
authors.forename: Attila
authors.initials: A
authors.lastname: Varga
authors.affiliation: MTA-SE Pathobiochemistry Research Group, Semmelweis University.
authors.forename: Bianka
authors.initials: B
authors.lastname: Gurbi
authors.affiliation: MTA-SE Pathobiochemistry Research Group, Semmelweis University.
authors.forename: Pál
authors.initials: P
authors.lastname: Gyulavári
authors.affiliation: MTA-ELTE Research Group of Peptide Chemistry, Eötvös Loránd University.
authors.forename: Gábor
authors.initials: G
authors.lastname: Mező
authors.affiliation: Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University.
authors.forename: Tibor
authors.initials: T
authors.lastname: Vántus
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002460:Cell Line; D016503:Drug Delivery Systems / Q000379:methods*; D005434:Flow Cytometry; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D006801:Humans; D011498:Protein Precursors; D011966:Receptors, LHRH / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D011498:Protein Precursors; D011966:Receptors, LHRH; C050866:progonadoliberin I; D007987:Gonadotropin-Releasing Hormone; C047717:LHRH, His(5)-Trp(7)-Tyr(8)-